Regeneron Pharmaceuticals (NasdaqGS:REGN) recently entered a licensing agreement with Telesis Bio Inc. to implement the Gibson SOLA™ platform, aiming to boost the company’s efficiency in the biotech ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its ...

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...